Introduction
============

Pulmonary arterial hypertension (PAH) is a cardiovascular complication that causes death in thalassemic patients. PAH in thalassemia was reported with a high incidence in several studies.[@b1-ijgm-7-525]--[@b4-ijgm-7-525] There was evidence that PAH in thalassemia is associated with platelet activation.[@b5-ijgm-7-525]--[@b7-ijgm-7-525] Acetylsalicylic acid (ASA) lowers the thromboxane--prostaglandin I~2~ (Tx--PGI~2~) ratio in PAH and inhibits platelet activity. A previous cohort study found that the rise of arterial partial pressure of oxygen (PaO~2~) in ten out of the 12 β-thalassemic patients after ASA ten grains or persantin administration for 2--4 weeks indicates that the observed hypoxemia is due to reversible platelet aggregation.[@b9-ijgm-7-525] A recent study showed that ASA decreased pulmonary artery pressure, reduced right ventricular hypertrophy, and improved survival in the monocrotaline animal model of PAH.[@b10-ijgm-7-525] The erythrocytes and platelets of thalassemic patients contained higher levels of reactive oxygen and lower levels of intracellular glutathione than normal erythrocytes and platelets[@b11-ijgm-7-525] that play a role in oxidative stress, thereby leading to the proper therapy.

The standard medication for PAH in thalassemia is not well understood. The mechanism of action of the drugs for PAH is not known. Studies of antiplatelet therapy are required before there are conclusive treatment guidelines for thalassemic patients with PAH. In clinical practice, ASA has been used to prevent and treat PAH in thalassemia in Thailand. There were few studies of ASA or antiplatelet therapy in these cases. The aim of the research was to compare after 1 year of follow-up the pulmonary artery systolic pressure (PASP) of patients with thalassemia and PAH to whom ASA was and was not prescribed.

Materials and methods
=====================

A retrospective cohort study was conducted at the hematological outpatient clinic at Chiang Rai Hospital, Chiang Rai, Thailand. All new adult (aged ≥15 years) cases of thalassemia with PAH defined as PASP \>35 mmHg by Doppler echocardiography (echo) from January 2007 to January 2012 were evaluated and followed from the first month to 12 months later. The patients were classified into two groups. In one group, ASA 81 mg was prescribed daily for 1 year, and in another group, no ASA was prescribed, due to contraindications for ASA (including bleeding, gastrointestinal side effects, and thrombocytopenia \[platelets \<100×10^3^/μL\]). The physician evaluated drug compliance and side effects. PASP, functional class status, clinical right heart failure, and oxygen saturation were measured at baseline and at the end of 12 months. The functional class status was defined by the New York Heart Association (NYHA) classification.[@b12-ijgm-7-525] Patients with other causes of PAH or who used other antiplatelets and/or anticoagulants were excluded. The study protocol was approved by the Institutional Research Ethics Committee and was carried out in accordance with the Declaration of Helsinki.

Echo procedure
--------------

Echo was done by the same cardiologist and the patients' history was blinded. Complete two-dimensional, M-mode, and Doppler (pulsed wave, continuous wave, and color) echo was performed at rest. In the study patients, a tricuspid regurgitation jet was sought from all available midprecordial and apical positions until a flow signal with the maximum spectral representation of the highest velocities was obtained. Peak velocity was recorded from a holosystolic regurgitant jet. From the maximum velocity (V) of the regurgitant jet, the systolic pressure gradient (∆P) between the right ventricle and the right atrium was calculated by modified Bernoulli equation (∆P = 4V[@b2-ijgm-7-525]).[@b13-ijgm-7-525] Right atrial pressure was estimated by the response of the inferior vena cava diameter to inspiration. Right atrial pressure was assumed to be 5 mmHg if the inferior vena cava completely collapsed with inspiration, 10 mmHg if the inferior vena cava dia meter decreased \>50% during inspiration, and 15 mmHg if it decreased \<50%. If the inferior vena cava diameter was \>2.5 cm and reduced by \<50% during inspiration, right atrial pressure was assumed to be 20 mmHg.[@b14-ijgm-7-525] Adding the transtricuspid gradient to the mean right atrial pressure provided the right ventricular systolic pressure or peak systolic pulmonary arterial pressure in the absence of right ventricular outflow tract obstruction. PAH was defined as PASP \>35 mmHg.[@b15-ijgm-7-525] In cases with an absence of tricuspid regurgitation, at the end of the diastolic pulmonic regurgitant the velocity was calculated using the pressure gradient between the pulmonary artery and right ventricular end diastolic pressure: pulmonary artery pressure =4 (VPR)[@b2-ijgm-7-525] + right atrial pressure.

Statistical analysis
--------------------

The baseline characteristics were compared using exact probability tests for categorical variables; Student's *t*-test or Wilcoxon rank-sum test was used to compare the mean difference of continuous variables. Propensity score adjustment was used to control confounding by ASA indication and contraindication. Propensity scores for prescribing ASA versus no ASA were calculated from a logistic regression model that estimated the likelihood of prescribing ASA based on the observed patient characteristics. Gaussian and an exponential risk regression were carried out. Univariable and multivariable regression analyses were used to evaluate the effects of ASA. Data are presented by frequency, percentage, mean, standard deviation (SD), beta coefficient, 95% confidence interval \[CI\], and *P*-value. All statistical analyses were two-tailed. A *P*-value of \<0.05 was considered statistically significant.

Results
=======

A total of 63 thalassemia patients with PAH, 53 with E/β-thal, six with homozygous β-thal, and four with Hb H disease were evaluated. There were 47 (74.6%) in the ASA group and 16 (25.4%) in the no ASA group. Patients in the second group had the following contraindications for ASA: seven (43.7%) bleeding, seven (43.7%) gastrointestinal side effects, and two (12.5%) thrombocytopenia. The mean age was 35.9±16.8 years and 28.3±14.1 years, and the mean PASP was 51.9±13.7 mmHg and 45.6±9.9 mmHg in the ASA group and the no ASA group. The baseline characteristics of the patients did not differ significantly except for red cell transfusion and right ventricular diameter ([Table 1](#t1-ijgm-7-525){ref-type="table"}). The patients in the ASA group received fewer blood transfusions during the follow-up time of 12 months than those without ASA (6.2±4.8 vs 11.0±4.6 units, *P*=0.002), and the ASA group had wider right ventricular diameter than the no ASA group (29.5±5.8 vs 25.5±4.2 mm, *P*=0.016).

During the follow-up period of 12 months, PASP increased in 12 of 47 (25.5%) patients in the ASA group and in three of 16 (18.7%) in the no ASA group. Echo findings showed that the patients in the ASA group had a higher mean PASP than the no ASA group, but there was no statistical difference.

After adjusting for propensity score (based on type of thalassemia, splenectomy, O~2~ saturation, NYHA classification, red cell transfusion, clinical right heart failure, hemoglobin level, platelet count, nucleated red cell, serum ferritin level, baseline PASP, left ventricular ejection fraction, main pulmonary artery diameter, right ventricular diameter, right ventricular systolic function, and diastolic function), there were no statistically significant differences in the functional class status, clinical right heart failure, and oxygen saturation between the two groups ([Table 3](#t3-ijgm-7-525){ref-type="table"}). ASA, as compared with no ASA, did not significantly reduce PASP (adjusted difference −0.95; 95% CI −16.99 to 15.10; *P*=0.906). None of the patients had deep vein thrombosis, ischemic stroke and pulmonary embolism.

Discussion
==========

In the present study, ASA did not improve the functional class status, clinical right heart failure, and oxygen saturation and did not have a significant effect on PASP after 12 months. Both the ASA and the no ASA groups had reduced PASP by −4.7±11.0 mmHg and −4.3±7.1 mmHg with no clinical or statistical significance. The results of this study were similar to those of a randomized clinical trial of ASA and simvastatin for PAH, which concluded that the results did not support the routine treatment of patients with PAH with these medications.[@b16-ijgm-7-525] And thalassemia patients who experienced a thromboembolic event and received ASA afterwards had a lower recurrence of thromboembolic event compared with those who were not taking ASA, although these differences were not statistically significant.[@b17-ijgm-7-525] Subgroup analysis of E/β-thal; ASA, as compared with no ASA, did not significantly reduce the PASP (adjusted difference −3.62; 95% CI −11.84 to 4.60; *P*=0.225). For the transfusion- and nontransfusion-dependent patients, ASA did not significantly change the PASP.

In contrast to the previous study that reported that there was a rise of arterial PaO~2~ after high-dose ASA administration in thalassemia patients with PAH,[@b9-ijgm-7-525] we found that oxygen saturation rose in the patients who had received low-dose ASA but without statistical significance (adjusted difference 0.31; 95% CI −1.71 to 2.33; *P*=0.757).

PAH developed in thalassemic patients because of platelet activation and hypercoagulable state.[@b18-ijgm-7-525],[@b19-ijgm-7-525] Therefore, it was reasonable that antiplatelet therapy alone may be less effective for PAH in thalassemia. Its role in the prevention of PAH in thalassemia should be evaluated.

Further studies of PAH management will be required before conclusive recommendations can be made for anti-platelet or anticoagulant therapy or prevention for high risk of PAH in thalassemia (postsplenectomy status[@b3-ijgm-7-525]).

The present study may have some limitations, as it was not a randomized controlled trial, the duration of treatment was only 12 months, and the 6-minute walk test was not used as a clinical outcome due to its retrospective nature. The lack of cardiac catheterization to confirm PASP is a limitation for a therapeutic trial of PAH.[@b20-ijgm-7-525] However, echo is more sensitive and is a commonly used noninvasive tool to screen PAH. More evidence from observational studies or preferably randomized clinical trials may be required before it can be concluded that ASA would offer any beneficial effects to these patients.

The current therapies for PAH in thalassemia include the use of sildenafil[@b21-ijgm-7-525],[@b22-ijgm-7-525] and bosentan.[@b23-ijgm-7-525] However, a large cohort of patients on the topic are needed before definite recommendations can be made.

Conclusion
==========

The present findings suggested that low-dose ASA may not have a beneficial effect on PASP after 1-year treatment of PAH in thalassemia.
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###### 

Baseline characteristics of the patients[a](#tfn1-ijgm-7-525){ref-type="table-fn"}

  Characteristic                                                                      ASA, n=47     No ASA, n=16   *P*-value
  ----------------------------------------------------------------------------------- ------------- -------------- -----------
  Male (n \[%\])                                                                      16 (34.0)     6 (37.5)       0.515
  Age (years)                                                                         35.9±16.8     28.3±14.1      0.112
  Weight (kg)                                                                         42.3±6.2      39.0±8.3       0.104
  Height (cm)                                                                         150.6±8.2     147.0±12.1     0.192
  Type of thalassemia (n \[%\])                                                                                    
   Hemoglobin E/β-thalassemia                                                         41 (87.2)     12 (75.0)      0.288
   Homozygous β-thalassemia                                                           3 (6.4)       3 (18.7)       
   Hemoglobin H disease                                                               3 (6.4)       1 (6.3)        
  Splenectomy (n \[%\])                                                               29 (61.7)     13 (81.2)      0.129
  Red cell transfusion (units/year)                                                   6.2±4.8       11±4.6         0.002
   Transfusion dependent (≥9 units/year) (n \[%\])                                    14 (29.8)     12 (75.0)      0.003
   Nontransfusion dependent                                                           33 (70.2)     4 (25.0)       
  Functional class status: NYHA (n \[%\])                                                                          
   I                                                                                  5 (10.6)      0              0.463
   II                                                                                 38 (80.9)     14 (87.5)      
   III                                                                                4 (8.5)       2 (12.5)       
  Clinical right heart failure[\*](#tfn2-ijgm-7-525){ref-type="table-fn"} (n \[%\])   8 (17.0)      1 (6.3)        0.270
  Systolic blood pressure (mmHg)                                                      106.9±15.0    102.0±9.2      0.218
  Diastolic blood pressure (mmHg)                                                     62.6±8.0      60.5±6.8       0.352
  Pulse rate (/minute)                                                                85.0±10.4     90.8±13.1      0.078
  Oxygen saturation (%)                                                               95.9±2.1      96.4±1.6       0.374
  Hemoglobin (g/dL)                                                                   6.3±0.9       6.3±0.8        0.903
  Corrected WBCs (×10^3^/μL)                                                          11.1±5.8      14.4±5.7       0.054
  Platelets (×10^3^/μL)                                                               369.3±28.7    501.4±27.5     0.114
  Nucleated RBCs/100 WBCs                                                             192.1±248.4   117.5±91.0     0.888
  PT (seconds)                                                                        13.1±1.2      13.4±1.0       0.394
  PTT (seconds)                                                                       31.2±3.1      30.7±3.1       0.560
  INR                                                                                 1.2±0.1       1.2±0.0        0.339
  Aspartate transaminase (IU/L)                                                       66.5±48.0     72.0±48.2      0.540
  Alanine transaminase (IU/L)                                                         51±35         52±37          0.993
  Total bilirubin (mg/dL)                                                             2.7±1.3       2.6±1.2        0.781
  HBsAg positive (n \[%\])                                                            2 (4.2)       0              0.554
  Anti-HCV positive (n \[%\])                                                         5 (10.6)      4 (25)         0.157
  Serum creatinine (mg/dL)                                                            0.6±0.1       0.71±0.2       0.165
  Serum ferritin (μg/L)                                                               3,006±2797    3,345±1510     0.067
  Echocardiographic findings                                                                                       
   PASP (mmHg)                                                                        51.9±13.7     45.6±9.9       0.096
   PASP (mmHg) severity (n \[%\])                                                                                  
    36--50 mmHg (mild)                                                                25 (53.2)     12 (75.0)      0.404
    51--70 mmHg (moderate)                                                            15 (31.9)     3 (18.7)       
    \>70 mmHg (severe)                                                                7 (14.9)      1 (6.3)        
   LVEF (%)                                                                           62.7±7.8      63.5±7.4       0.718
   LVESd (mm)                                                                         9.5±2.1       9.0±2.2        0.445
   LVEDd (mm)                                                                         51.5±6.0      49.4±7.6       0.256
   MPAd (mm)                                                                          25.9±4.2      25.0±3.0       0.464
   RVd (mm)                                                                           29.5±5.8      25.5±4.2       0.016
   Poor right ventricular systolic function (n \[%\])                                 7 (14.8)      0              0.114
   Diastolic function, n (%)                                                                                       
    Mitral valve E:A ratio                                                            1.4±0.4       1.2±0.2        0.515
    Mitral valve DT (ms)                                                              199±35        202±88         0.941
  Propensity score                                                                    0.8±0.2       0.2±0.2        \<0.001

**Notes:**

Values shown are mean ± standard deviation unless otherwise specified;

elevated jugular venous pressure, hepatojugular reflux, and edema.

**Abbreviations:** ASA, acetylsalicylic acid; DT, deceleration time; E:A, ratio of the early (E) to late (A) ventricular filling velocities; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; INR, international normalized ratio; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESd, left ventricular end systolic diameter; MPAd, main pulmonary artery diameter; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; PT, prothrombin time; PTT, partial thromboplastin time; RBCs, red blood cells; RVd, right ventricular diameter; WBCs, white blood cells.

###### 

Clinical outcomes and echocardiographic findings at 12 months[a](#tfn4-ijgm-7-525){ref-type="table-fn"}

  Outcome                                               ASA, n=47   No ASA, n=16   *P*-value
  ----------------------------------------------------- ----------- -------------- -----------
  Functional class status: NYHA (n \[%\])                                          
   I                                                    5 (10.6)    1 (6.3)        0.841
   II                                                   39 (83.0)   15 (93.7)      
   III                                                  3 (6.4)     0              
  Clinical right heart failure (n \[%\])                6 (12.7)    1 (6.3)        0.424
  O~2~ saturation (%)                                   96.7±2.2    97.1±1.7       0.492
  Echocardiographic findings                                                       
   PASP (mmHg)                                          47.2±16.9   41.2±11.6      0.197
   LVEF (%)                                             64.9±7.5    64.1±6.4       0.700
   LVESd (mm)                                           9.6±2.0     9.8±2.6        0.759
   LVEDd (mm)                                           50.6±5.6    48.7±6.9       0.266
   MPAd (mm)                                            25.8±4.3    24.5±3.3       0.249
   RVd (mm)                                             29.7±6.2    26.6±3.0       0.057
   Poor right ventricular systolic function (n \[%\])   6 (12.7)    0              0.158
   Diastolic function                                                              
    Mitral valve E:A ratio                              1.5±0.5     1.7±0.9        0.395
    Mitral valve DT (ms)                                205±28      217±29         0.382

**Note:**

Values shown are mean ± standard deviation unless otherwise specified.

**Abbreviations:** ASA, acetylsalicylic acid; DT, deceleration time; E:A, ratio of the early (E) to late (A) ventricular filling velocities; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESd, left ventricular end systolic diameter; MPAd, main pulmonary artery diameter; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RVd, right ventricular diameter.

###### 

Effect of acetylsalicylic acid on clinical outcomes and echocardiographic findings

  Outcome[a](#tfn7-ijgm-7-525){ref-type="table-fn"}                                            Adjusted difference[\*](#tfn6-ijgm-7-525){ref-type="table-fn"} (95% CI)   *P*-value
  -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -----------
  Functional class status: NYHA class (n \[%\])[b](#tfn8-ijgm-7-525){ref-type="table-fn"}      0.30 (−3.18 to 3.78)                                                      0.865
  Clinical right heart failure (n \[%\])[c](#tfn9-ijgm-7-525){ref-type="table-fn"}             −0.001 (−3.86 to 3.86)                                                    0.999
  O~2~ saturation (%)                                                                          0.31 (−1.71 to 2.33)                                                      0.757
  Echocardiographic findings                                                                                                                                             
   PASP (mmHg)                                                                                 −0.95 (−16.99 to 15.10)                                                   0.906
   LVEF (%)                                                                                    −0.66 (−9.24 to 7.92)                                                     0.877
   LVESd (mm)[d](#tfn10-ijgm-7-525){ref-type="table-fn"}                                       −0.76 (−4.08 to 2.56)                                                     0.655
   LVEDd (mm)                                                                                  −1.47 (−8.50 to 5.56)                                                     0.673
   MPAd (mm)                                                                                   1.19 (−2.67 to 5.06)                                                      0.534
   RVd (mm)[d](#tfn10-ijgm-7-525){ref-type="table-fn"}                                         0.83 (−4.62 to 6.29)                                                      0.765
   Poor right ventricular systolic function, n (%)[c](#tfn9-ijgm-7-525){ref-type="table-fn"}   15.37 (−2,219 to 2,250)                                                   0.989
   Diastolic function                                                                                                                                                    
    Mitral valve E:A ratio[d](#tfn10-ijgm-7-525){ref-type="table-fn"}                          0.46 (−1.78 to 2.70)                                                      0.687
    Mitral valve DT (ms)[d](#tfn10-ijgm-7-525){ref-type="table-fn"}                            −25.62 (−47.89 to −3.36)                                                  0.024

**Notes:**

Adjusted for propensity score (type of thalassemia, splenectomy, O~2~ saturation, NYHA classification, red cell transfusion, clinical right heart failure, hemoglobin level, platelet count, nucleated red cell, serum ferritin level, baseline PASP, LVEF, MPAd, RVd, right ventricular systolic function, and diastolic function).

Gaussian regression unless otherwise indicated;

ordered logistic regression;

generalized linear models: extensions to the binomial family;

generalized linear models: Poisson regression.

**Abbreviations:** CI, confidence interval; DT, deceleration time; E:A, ratio of the early (E) to late (A) ventricular filling velocities; LVEF, left ventricular ejection fraction; MPAd, main pulmonary artery diameter; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RVd, right ventricular diameter.
